Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-BAC for relapsed or refractory diffuse large B-cell lymphoma
ChiCTR2000033337Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab, bendamustine and cytarabine in diffuse large B-cell lymphoma (DLBCL), sponsored by The Second Xiangya Hospital. Primary endpoint: Overall response rate. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
rituximabbendamustinecytarabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000033337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033337.